Brooks is CEO of Infinity BiologiX, the former RUCDR Infinite Biologics lab at the New Brunswick campus where the COVID-19 saliva test, which has made testing for the virus in certain populations much easier, was developed.
Spinning IBX off into a new company was a “tremendous accomplishment,” said Brian Strom, head of Rutgers Biomedical and Health Sciences. The move allowed the company to grow and to create strategic and innovative solutions in all market segments.
“The new capital investment in the business [by Viking Global Investors LP in New York] will allow us to expand both physically and technologically to meet the demands of our current and future clients across all of our services,” Brooks said. “I am honored to have been chosen to lead Infinity BiologiX and to work with our incredible team on this new and exciting journey.”
